Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05760287

Echocardiographic Characterization of Cardiac Amyloidosis

This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy) will be enrolled.

The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype.

Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiac Amyloidosis Amyloid Neuropathies Amyloid Neuropathies, Familial Amyloidosis Amyloidosis, Familial Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Neurodegenerative Diseases Neuromuscular Diseases Nutritional and Metabolic Diseases Peripheral Nervous System Diseases Proteostasis Deficiencies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit.

Exclusion criteria

  • missing data
  • decline to the study participation

Treatment and study plan

Primary outcomes

  1. changes in echocardiographic parameters (in patients receiving or not specific treatment)

    Time frame: 6 months

    variation in global longitudinal strain, diastolic parameters and degree of ventricular hypertrophy

  2. cardiovascular outcomes

    Time frame: 24 months

    composite endpoint of death and heart failure hospitalization

Secondary outcomes

  1. major cardiac arrhythmias

    Time frame: 24 months

    bradyarrhythmia, new-onset atrial fibrillation, ventricular tachycardia

Study contacts

Contact information is provided by the study sponsor or research team.

Francesca Graziani, MD

CONTACT

[email protected]

00390630154432

maria chiara meucci, MD

CONTACT

[email protected]

00390630154432

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study

Acronym: Echo-AMY

Important dates

Study start
2022
Primary completion
2030
Study completion
2031
First posted
Mar 8, 2023
Registry last updated
Mar 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.